UFP Technologies, Inc. reported a notable increase in financial performance for the second quarter of 2026, with net sales reaching $173.964 million, a 15.1% rise from $151.176 million in the same period of 2025. For the first half of 2026, net sales totaled $328.166 million, up 9.6% from $299.324 million year-over-year. The company's gross profit for the second quarter was $50.918 million, translating to a gross margin of 29.3%, an improvement from 28.8% in the prior year. Net income for the quarter was $20.851 million, or $2.68 per diluted share, compared to $17.180 million, or $2.21 per diluted share, in the same quarter of 2025.
The company experienced significant changes in its operational metrics, with organic sales growth of 12.4% for the second quarter and 6.8% for the first half of 2026. This growth was primarily driven by increased sales in the Surfaces and Support, Cardiovascular, Infection Control, and Orthopedics sub-markets. UFP Technologies also noted a rise in selling, general, and administrative (SG&A) expenses, which increased by 21.8% to $22.753 million for the second quarter, attributed to higher headcount and variable compensation costs, including expenses related to a CEO transition.
In terms of strategic developments, UFP Technologies has been active in acquisitions, having completed several transactions in 2025, including the purchase of Techno Plastics Industries and Universal Plastics & Engineering Company. These acquisitions are expected to enhance the company's capabilities in manufacturing precision components for medical devices. The company also reported a decrease in long-term debt, which stood at $104.805 million as of June 30, 2026, down from $122.955 million at the end of 2025, reflecting a focus on improving its financial leverage.
Operationally, UFP Technologies reported a total employee headcount increase, which has contributed to productivity challenges, particularly in its AJR operations due to workforce turnover. The company is actively addressing these issues by recruiting legally eligible associates. Additionally, UFP Technologies has seen a significant increase in accounts receivable, which rose by $30.5 million, reflecting the higher sales volume in the second quarter. The company’s cash and cash equivalents decreased to $9.045 million from $20.301 million at the end of 2025, indicating a need for careful cash management moving forward.
Looking ahead, UFP Technologies remains optimistic about its growth trajectory, emphasizing its commitment to enhancing operational efficiencies and exploring further acquisition opportunities. The company is also adapting to the evolving tariff landscape and managing the implications of recent cybersecurity incidents, which have not materially impacted its operations to date. Overall, UFP Technologies is positioned to leverage its recent growth and strategic initiatives to drive future performance.
About UFP TECHNOLOGIES INC
UFP Technologies, Inc. designs and manufactures custom engineered solutions primarily for the medical device, aerospace, defense, automotive, and industrial markets. Its core products include medical device components, sterile packaging, automotive interior parts, and aerospace composites. The company leverages advanced materials, engineering expertise, and proprietary technology to serve top OEMs worldwide, emphasizing innovation, quality, and regulatory compliance in highly specialized, niche segments.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov